Schering-Plough cancels trials on respiratory indications for a Pharmacopeia-collaborated drug

By Ted A. Knutson

Washington, Dec. 1 - Pharmacopeia Drug Discovery Inc. said Thursday Schering-Plough Corp. informed it that Schering has discontinued the phase 1 clinical trials it began in December 2003 for a drug targeting a respiratory indication, which was developed from leads from collaboration between the two companies.

Schering-Plough also told Pharmacopeia that it expects to pursue the program for other indications, according to an 8-K filing with the Securities and Exchange Commission.

Pharmacopeia is a Princeton, N.J.-based biotechnology company.

Schering-Plough is a Kenilworth, N.J., pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.